GlassScriptPhysician profile
Morris M Elstein
NPI 1285600320
$3,639.28
in general payments reported to CMS, 2019-2025
39 companies · $459 in 2025
The $459 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $319 · 2021: $570 · 2022: $452 · 2023: $737 · 2024: $390 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.70 |
| Education | $190.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $779.10 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $765.47 | 2019-2023 | |
| Novo Nordisk INC | $271.49 | 2019-2025 | Wegovy |
| Merz North America, INC. | $224.11 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $205.80 | 2019-2023 | Contrave |
| Minerva Surgical, INC | $164.19 | 2019 | |
| Pfizer INC. | $105.00 | 2019-2022 | |
| Exact Sciences Corporation | $98.51 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $77.83 | 2025 | Gemtesa, Myfembree |
| Organon LLC | $74.30 | 2022-2025 | Nexplanon |
| Myovant Sciences INC. | $64.03 | 2021-2022 | |
| Hologic Sales and Service, LLC | $60.95 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $58.62 | 2019-2021 | |
| Lupin INC. | $46.15 | 2019-2020 | |
| Lilly USA, LLC | $45.62 | 2025 | Zepbound, Mounjaro |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $45.01 | 2022-2023 | Ova1 |
| Coloplast Corp | $39.24 | 2021-2023 | Altis |
| Mayne Pharma Commercial LLC | $37.33 | 2022-2023 | |
| Caldera Medical, INC | $35.88 | 2021 | |
| Scynexis, INC. | $34.20 | 2022 | |
| Millicent US INC | $34.19 | 2025 | Intrarosa, Femring, Femlyv |
| Avion Pharmaceuticals | $32.01 | 2022-2023 | Balcoltra |
| Idorsia Pharmaceuticals US INC | $31.80 | 2023-2024 | Quviviq |
| Evofem Biosciences, INC. | $31.13 | 2021-2022 | |
| Boston Scientific Corporation | $30.56 | 2022 | |
| Exeltis, USA INC. | $30.11 | 2021 | |
| Amag Pharmaceuticals, INC. | $29.05 | 2019 | |
| Eisai INC. | $24.57 | 2019 | |
| Provepharm INC. | $21.85 | 2025 | Bludigo |
| Covidien LP | $17.07 | 2020 | |
| Therapeuticsmd, INC. | $16.49 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.21 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.17 | 2023 | Seglentis |
| Duchesnay USA Incorporated | $15.08 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.37 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $13.80 | 2022 | |
| Agile Therapeutics, INC. | $13.32 | 2021 | |
| Allergan, INC. | $11.12 | 2019 | |
| Meditrina | $9.55 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Elstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.